These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 23689307

  • 1. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C, Zecca C, Linnebank M, Müller S, You X, Meier R, Borter E, Traber M.
    Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
    [Abstract] [Full Text] [Related]

  • 2. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.
    Beer K, Müller M, Hew-Winzeler AM, Bont A, Maire P, You X, Foulds P, Mårlind J, Curtius D.
    BMC Neurol; 2011 Nov 10; 11():144. PubMed ID: 22074056
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
    Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R.
    J Med Econ; 2012 Nov 10; 15(3):424-33. PubMed ID: 22217249
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A, Murray TJ, PROOF Study Investigators.
    Curr Med Res Opin; 2008 Apr 10; 24(4):1049-55. PubMed ID: 18315940
    [Abstract] [Full Text] [Related]

  • 5. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW, Stephen R, Seaman C, Rajagopalan K.
    Curr Med Res Opin; 2010 Mar 10; 26(3):663-74. PubMed ID: 20070144
    [Abstract] [Full Text] [Related]

  • 6. Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project.
    Arroyo E, Grau C, Ramo-Tello C, Parra J, Sánchez-Soliño O, GAP Study Group.
    Eur Neurol; 2011 Mar 10; 65(2):59-67. PubMed ID: 21212677
    [Abstract] [Full Text] [Related]

  • 7. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years.
    Oleen-Burkey M, Cyhaniuk A, Swallow E.
    J Med Econ; 2013 Mar 10; 16(3):397-406. PubMed ID: 23301877
    [Abstract] [Full Text] [Related]

  • 8. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 10; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E, Meyer K.
    Curr Med Res Opin; 2009 Jun 10; 25(6):1445-54. PubMed ID: 19422279
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
    Dembek C, White LA, Quach J, Szkurhan A, Rashid N, Blasco MR.
    Eur J Health Econ; 2014 May 10; 15(4):353-62. PubMed ID: 23615954
    [Abstract] [Full Text] [Related]

  • 12. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL, Copolymer-1 Treatment Study Principal Investigators.
    Acta Neurol Scand; 2006 Jun 10; 113(6):378-86. PubMed ID: 16674604
    [Abstract] [Full Text] [Related]

  • 13. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP.
    Adv Ther; 2008 Jul 10; 25(7):658-73. PubMed ID: 18641926
    [Abstract] [Full Text] [Related]

  • 14. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 10; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts.
    Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson K.
    J Med Econ; 2010 Sep 10; 13(3):464-71. PubMed ID: 20662760
    [Abstract] [Full Text] [Related]

  • 17. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B, Jacobs LD.
    Drugs; 2000 Mar 10; 59(3):401-10. PubMed ID: 10776827
    [Abstract] [Full Text] [Related]

  • 18. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, Maurer SL, Riester K, Davar G, Dawson K, Sandrock A, Avonex CIDP Study Group.
    Neurology; 2010 Feb 23; 74(8):651-7. PubMed ID: 20177118
    [Abstract] [Full Text] [Related]

  • 19. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
    Singer B, Bandari D, Cascione M, LaGanke C, Huddlestone J, Bennett R, Dangond F, REFORMS Study Group.
    BMC Neurol; 2012 Dec 06; 12():154. PubMed ID: 23216674
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.
    Neurology; 2009 Jun 09; 72(23):1976-83. PubMed ID: 19279320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.